One option for macular degeneration cuts treatment costs from $2,000 to $50. April 4, 2011— -- One drug costs $50 per dose. The other costs $2,000 per dose. Now, new research shows that the drug ...
The DUO-O trial showed significant improvement in progression-free survival with Imfinzi, Avastin, and Lynparza, but no ...
When pembrolizumab was added to paclitaxel with or without bevacizumab in platinum-resistant ovarian cancer, significant ...
Roche’s CEO Thomas Schinecker said the drugmaker is continuing talks with the US government over drug pricing reforms, as ...
FDA issues Complete Response Letter (CRL) for resubmitted ONS-5010 BLA Outlook Therapeutics plans to work with FDA to address the Agency’s issues Company to host a conference call and webcast today, ...
The addition of tiragolumab to Tecentriq and Avastin did not significantly improve progression-free survival in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback